Mast Therapeutics

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1995
Size (employees)
6 (est)
Mast Therapeutics was founded in 1995 and is headquartered in San Diego, US

Mast Therapeutics Office Locations

Mast Therapeutics has an office in San Diego
San Diego, US (HQ)
500 3611 Valley Centre Dr

Mast Therapeutics Data and Metrics

Mast Therapeutics Financial Metrics

Mast Therapeutics's revenue was reported to be $94 k in Q1, 2017
USD

Revenue (Q1, 2017)

94 k

Net income (Q1, 2017)

(5.9 m)

EBIT (Q1, 2017)

(5.7 m)

Market capitalization (18-Aug-2017)

75.9 m

Cash (31-Mar-2017)

7.8 m
Mast Therapeutics's current market capitalization is $75.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

128 k

Revenue growth, %

(100%)

R&D expense

12.9 m19.4 m28.3 m20.8 m

General and administrative expense

9.3 m

Operating expense total

12.9 m19.4 m28.3 m30.1 m

EBIT

(21.5 m)(29.3 m)(39.4 m)(36.5 m)

EBIT margin, %

(28481%)

Interest expense

2.1 m

Interest income

60.3 k69 k130 k122 k

Pre tax profit

(21.5 m)(28.7 m)(39.8 m)(38.5 m)

Income tax expense

2.4 m

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

45 k94 k

R&D expense

4.8 m5.4 m6 m7.7 m7.3 m7.9 m7.8 m5.1 m1.4 m

General and administrative expense

2.4 m2.5 m3.6 m2.4 m2.5 m2.8 m2.4 m2.1 m1.6 m

Operating expense total

7.2 m7.9 m9.6 m10.1 m9.8 m10.7 m10.2 m7.2 m3 m

EBIT

(7.2 m)(7.9 m)(9.7 m)(10.2 m)(9.8 m)(10.7 m)(10.2 m)(7.2 m)(5.7 m)

EBIT margin, %

(16002%)(6061%)

Interest expense

1 k101 k519 k512 k948 k178 k

Interest income

16.9 k17.4 k30 k32 k32 k39 k36 k31 k11 k

Net Income

(7.2 m)(7.9 m)(9.6 m)(10.2 m)(9.9 m)(11.2 m)(10.7 m)(8.2 m)(5.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

25.7 m35.8 m23.1 m8.5 m

Inventories

1.1 m1.1 m1.3 m903 k

Current Assets

45.5 m58.4 m42.3 m12.2 m

PP&E

105.7 k188 k226 k99 k

Goodwill

3 m3 m3 m3 m

Total Assets

55.2 m70.5 m54.2 m17.9 m

Accounts Payable

963.9 k1.4 m2.6 m626 k

Current Liabilities

4.8 m8.4 m23.2 m4.9 m

Total Liabilities

8.2 m

Additional Paid-in Capital

254.2 m293.7 m298.7 m320.6 m

Retained Earnings

(235.1 m)(275 m)(311.1 m)

Total Equity

47.8 m58.7 m23.9 m9.8 m

Financial Leverage

1.2 x1.2 x2.3 x1.8 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

26.4 m26 m27.9 m21.2 m32.2 m23.5 m24.5 m20.5 m7.8 m

Current Assets

47.6 m44.1 m50.6 m44.8 m51.4 m38.2 m35.8 m28.3 m8.2 m

PP&E

186.3 k185.7 k248 k230 k250 k199 k171 k148 k88 k

Goodwill

3 m3 m3 m3 m3 m3 m3 m3 m3 m

Total Assets

59.4 m56.2 m62.7 m56.8 m63.4 m50.1 m47.7 m40.1 m13.9 m

Accounts Payable

1.2 m1.2 m2.3 m2 m2.9 m2.5 m2.3 m1.5 m502 k

Current Liabilities

5.7 m7.5 m9.2 m10.8 m13.5 m22.7 m25.4 m20.9 m6.6 m

Additional Paid-in Capital

270.1 m273 m294.7 m297.3 m298.2 m306.7 m313.1 m318 m321 m

Retained Earnings

(220 m)(227.8 m)(244.7 m)(254.9 m)(264.8 m)(286.2 m)(296.9 m)(305 m)(316.9 m)

Total Equity

50.2 m45.2 m50.1 m42.5 m33.5 m20.7 m16.4 m13.2 m4.4 m

Financial Leverage

1.2 x1.2 x1.3 x1.3 x1.9 x2.4 x2.9 x3 x3.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)

Depreciation and Amortization

39.5 k85 k146 k99 k

Cash From Operating Activities

(17.8 m)(24.6 m)(32.9 m)(37.3 m)

Purchases of PP&E

(46.8 k)(147 k)(165 k)(8 k)

Cash From Investing Activities

(4.8 m)481 k3.4 m15.2 m

Cash From Financing Activities

25.7 m34.3 m16.8 m7.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.2 m)(7.9 m)(9.6 m)(10.2 m)(9.9 m)(11.2 m)(10.7 m)(8.2 m)(5.9 m)

Depreciation and Amortization

22.5 k25.8 k30 k37 k38 k32 k30 k24 k11 k

Accounts Payable

1.2 m1.2 m2.3 m2 m2.9 m2.5 m2.3 m1.5 m502 k
USDY, 2017

Revenue/Employee

15.7 k

Financial Leverage

3.2 x

Mast Therapeutics Market Value History

Traffic Overview of Mast Therapeutics

Mast Therapeutics Online and Social Media Presence

Mast Therapeutics Company Life and Culture

You may also be interested in